The USPTO issued patent US12595270B2 for a benzo nitrogen-containing heteroaromatic ring derivative as shown in general formula (I), covering the compound itself, stereoisomers, deuterates, solvates, prodrugs, metabolites, and pharmaceutical salts/co-crystals, along with intermediate compounds, preparation methods, and therapeutic applications for complement factor B-associated diseases. The patent carries CPC classifications spanning C07D heterocyclic chemistry (C07D 498/10, C07D 495/10, C07D 401/06, etc.) and A61K pharmaceutical compositions (A61K 31/438, A61K 31/454, etc.).

For pharmaceutical companies and researchers developing complement factor B inhibitors, this patent establishes intellectual property barriers around a specific heterocyclic compound family for therapeutic use. Competitors pursuing similar complement pathway targets must either design around these claims, pursue licensing arrangements with the assignee, or demonstrate non-infringement through alternative compound structures.